The peptide problem: Hype is outrunning the evidence The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The peptide problem: Hype is outrunning the evidence Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest